Ocumension Therapeutics: The Approval Received For Marketing OT-703 In Hong Kong, A New Option For Patients With Diabetic Macular Edema Dec 20, 2023 20:51 HKT/SGT Ocumension Therapeutics ("Ocumension" or the "Company", together with its subsidiaries, collectively...
Ocumension Therapeutics Announces 2023 Interim Results Aug 24, 2023 23:35 HKT/SGT Expanded Hospital NetworkHealthy Sales of the Company's Core Products1H 2023's Operating Revenue Surged 90% to RMB104 million
Ocumension Therapeutics Announces 2022 Annual Results Mar 30, 2023 22:29 HKT/SGT Youshiying (OT-401), Company's Core Product, Commercialized ahead of ScheduleSpeed up the Launch of New Products
Ocumension Therapeutics Announces Inclusion of Its Shares in the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect Programs Mar 13, 2023 18:30 HKT/SGT
Ocumension Therapeutics Issues Positive Profit Alert for 2022 Annual Results Feb 14, 2023 10:57 HKT/SGT Total Revenue And Gross Profit Expected To Surge Of Between 176% And 183% And 171% to 179% Respectively
Ocumension Therapeutics Announces The Completion Of The Phase I Clinical Trial Of Its Class I New Drug For The Treatment Of Dry Eye -- OT-202 Feb 03, 2023 10:01 HKT/SGT